Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.475 -0.245 (-4.28%)
Streaming Delayed Price Updated: 12:06 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For May 5, 2025
Via Benzinga
Retail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial Data
Traders flagged a key technical level at $4.65 and raised concerns over an outlier patient in the Tupelo trial, with attention now turning to management’s commentary during the earnings call. 
Via Stocktwits
Topics Earnings
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
How Do Investors Really Feel About Recursion Pharmaceuticals?
Via Benzinga
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
From FN Media Group LLC
Via GlobeNewswire
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT 
From Recursion Pharmaceuticals
Via GlobeNewswire
3 Monster Stocks to Hold for the Next 10 Years
They're not just leaders of their industry. Their underlying businesses are also on the verge of enormous growth. 
Via The Motley Fool
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?
Via The Motley Fool
Topics Animal Testing Artificial Intelligence Intellectual Property
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News
Via Stocktwits
Topics Animal Testing Artificial Intelligence Stocks
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods. 
Via Benzinga
Topics Animal Testing
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX
Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025. 
Via Stocktwits
Topics Animal Testing
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty. 
Via Benzinga
The market is filled with gapping stocks in Friday's session.
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Why Recursion Pharmaceuticals Stock Is Skyrocketing Today
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
Recursion Pharmaceuticals Shares Are Up Today: what's Going On?
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Friday after the U.S. Food and Drug Administration announced a significant policy change that could reshape the drug... 
Via Benzinga
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Nvidia-Backed Recursion Pharma Soars After-Hours As FDA Eyes AI Over Animal Testing For Drugs: Retail Traders Elated
Recursion is a clinical-stage biotech firm using AI, machine learning, and automation to accelerate drug discovery. 
Via Stocktwits
Topics Animal Testing Artificial Intelligence
Wondering what's happening in today's after-hours session?
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements
Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing... 
Via Benzinga
Topics Animal Testing
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors 
From Recursion Pharmaceuticals
Via GlobeNewswire
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
Via The Motley Fool
Topics Bankruptcy Economy World Trade
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Via The Motley Fool
Topics Government World Trade
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.